全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review

DOI: 10.1155/2011/374012

Full-Text   Cite this paper   Add to My Lib

Abstract:

Individuals who carry an inherited mutation in the breast cancer 1 (BRCA1) and BRCA2 genes have a significant risk of developing breast and ovarian cancer over the course of their lifetime. As a result, there are important considerations for the clinician in the counseling, followup and management of mutation carriers. This review outlines salient aspects in the approach to patients at high risk of developing breast and ovarian cancer, including criteria for genetic testing, screening guidelines, surgical prophylaxis, and chemoprevention. 1. Introduction Research into the hereditary breast and ovarian cancer genes, breast cancer 1 (BRCA1) and BRCA2, is an area of ongoing discovery in the molecular biology of cancer. For clinicians, it can be an overwhelming challenge to keep a breast with the latest studies and incorporate the most up-to-date evidence into their practice. There are many unique considerations that should be addressed when approaching patients with a predisposition to hereditary breast and ovarian cancer, including counseling, screening, and risk-reducing strategies. It is also important to understand which high-risk patients should be referred for genetic counseling for consideration of BRCA1/2 gene testing, an approach which is often underutilized in physicians’ practices [1]. In this review, the most relevant and current studies in hereditary breast and ovarian cancer epidemiology, screening, and prevention are outlined to guide the clinician in the management of high-risk individuals. Also highlighted is the role of BRCA in sporadic breast and ovarian cancer and the emergence of novel targeted therapies such as poly(ADP-ribose) polymerase inhibitors (PARPi) in BRCA1-deficient patients. 2. Cancer Risk in BRCA1- and BRCA2-Mutation Carriers In the general population, a woman’s lifetime risk of breast cancer is 1 in 8 [2], and the risk of ovarian cancer is 1 in 70 [3]. It is estimated that a BRCA1/2 mutation is found in 2–6% of breast cancer patients [4–6] and 10–15% of epithelial ovarian cancer patients [7–9]. In all women, the prevalence of a BRCA1 mutation is 1 in 800 to 1 in 1400 and the prevalence of BRCA2 mutation is slightly lower at 1 in 450 to 1 in 800 [6, 10, 11]. The lifetime risk of breast cancer in BRCA1- and BRCA2-mutation carriers is 45–80% [12, 13]. The lifetime risk of ovarian cancer is 45–60% for BRCA1-mutation carriers and 11–35% for BRCA2-mutation carriers [12–14]. A number of studies examining the incidence of breast cancer have reported a lower likelihood amongst BRCA2-mutation carriers compared to BRCA1-mutation

References

[1]  E. van Riel, C. C. Wárlám-Rodenhuis, S. Verhoef, E. Rutgers, and M. Ausems, “BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing,” European Journal of Cancer Care, vol. 19, no. 3, pp. 369–376, 2010.
[2]  American Cancer Society, “Breast cancer facts and figures 2009-2010,” 2009.
[3]  American Cancer Society, “Cancer facts and figures,” 2010.
[4]  M. R. McClain, G. E. Palomaki, K. L. Nathanson, and J. E. Haddow, “Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications,” Genetics in Medicine, vol. 7, no. 1, pp. 28–33, 2005.
[5]  E. M. John, A. Miron, G. Gong et al., “Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups,” Journal of the American Medical Association, vol. 298, no. 24, pp. 2869–2876, 2007.
[6]  K. E. Malone, J. R. Daling, D. R. Doody et al., “Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in White and Black American women ages 35 to 64 years,” Cancer Research, vol. 66, no. 16, pp. 8297–8308, 2006.
[7]  T. Pal, J. Permuth-Wey, J. A. Betts et al., “BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases,” Cancer, vol. 104, no. 12, pp. 2807–2816, 2005.
[8]  S. Zhang, R. Royer, S. Li et al., “Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer,” Gynecologic Oncology, vol. 121, no. 2, pp. 353–357, 2011.
[9]  H. A. Risch, J. R. McLaughlin, D. E. C. Cole et al., “Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada,” Journal of the National Cancer Institute, vol. 98, no. 23, pp. 1694–1706, 2006.
[10]  “Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group,” British Journal of Cancer, vol. 83, pp. 1301–1308, 2000.
[11]  K. E. Malone, J. R. Daling, C. Neal et al., “Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases,” Cancer, vol. 88, no. 6, pp. 1393–1402, 2000.
[12]  M. C. King, J. H. Marks, J. B. Mandell, and New York Breast Cancer Study Group, “Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2,” Science, vol. 302, no. 5645, pp. 643–646, 2003.
[13]  A. Antoniou, P. D. P. Pharoah, S. Narod et al., “Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies,” American Journal of Human Genetics, vol. 72, no. 5, pp. 1117–1130, 2003.
[14]  D. M. van der Kolk, G. H. de Bock, B. K. Leegte et al., “Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age,” Breast Cancer Research and Treatment, vol. 124, no. 3, pp. 643–651, 2010.
[15]  E. Warner, W. Foulkes, P. Goodwin et al., “Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer,” Journal of the National Cancer Institute, vol. 91, no. 14, pp. 1241–1247, 1999.
[16]  B. B. Roa, A. A. Boyd, K. Volcik, and C. S. Richards, “Ashkenazi jewish population frequencies for common mutations in BRCA1 and BRCA2,” Nature Genetics, vol. 14, no. 2, pp. 185–187, 1996.
[17]  B. Modan, P. Hartge, G. Hirsh-Yechezkel et al., “Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation,” New England Journal of Medicine, vol. 345, no. 4, pp. 235–240, 2001.
[18]  A. Veronesi, C. de Giacomi, M. D. Magri et al., “Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases,” BMC Cancer, vol. 5, article 70, 2005.
[19]  L. Kadouri, A. Hubert, Y. Rotenberg et al., “Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations,” Journal of Medical Genetics, vol. 44, no. 7, pp. 467–471, 2007.
[20]  D. Thompson and D. F. Easton, “Cancer incidence in BRCA1 mutation carriers,” Journal of the National Cancer Institute, vol. 94, no. 18, pp. 1358–1365, 2002.
[21]  C. Cybulski, B. Górski, J. Gronwald et al., “BRCA1 mutations and prostate cancer in Poland,” European Journal of Cancer Prevention, vol. 17, no. 1, pp. 62–66, 2008.
[22]  J. Suchy, C. Cybulski, B. Górski et al., “BRCA1 mutations and colorectal cancer in Poland,” Familial Cancer, vol. 9, no. 4, pp. 541–544, 2010.
[23]  D. Easton, “Cancer risks in BRCA2 mutation carriers: the breast cancer linkage consortium,” Journal of the National Cancer Institute, vol. 91, no. 15, pp. 1310–1316, 1999.
[24]  T. Kirchhoff, N. D. Kauff, N. Mitra et al., “BRCA mutations and risk of prostate cancer in ashkenazi jews,” Clinical Cancer Research, vol. 10, no. 9, pp. 2918–2921, 2004.
[25]  K. M. Murphy, K. A. Brune, C. Griffin et al., “Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%,” Cancer Research, vol. 62, no. 13, pp. 3789–3793, 2002.
[26]  R. M. Brohet, D. E. Goldgar, D. F. Easton et al., “Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group,” Journal of Clinical Oncology, vol. 25, no. 25, pp. 3831–3836, 2007.
[27]  T. Debniak, R. J. Scott, B. Górski et al., “Common variants of DNA repair genes and malignant melanoma,” European Journal of Cancer, vol. 44, no. 1, pp. 110–114, 2008.
[28]  D. P. Atchley, C. T. Albarracin, A. Lopez et al., “Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4282–4288, 2008.
[29]  N. Tung, Y. Wang, L. C. Collins et al., “Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features,” Breast Cancer Research, vol. 12, no. 1, article R12, 2010.
[30]  N. Loman, O. Johannsson, P. O. Bendahl, Borg, M. Fern?, and H. Olsson, “Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes,” Cancer, vol. 83, no. 2, pp. 310–319, 1998.
[31]  O. T. Johannsson, I. Idvall, C. Anderson et al., “Tumour biological features of BRCA1-induced breast and ovarian cancer,” European Journal of Cancer A, vol. 33, no. 3, pp. 362–371, 1997.
[32]  A. Musolino, M. A. Bella, B. Bortesi et al., “BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study,” Breast, vol. 16, no. 3, pp. 280–292, 2007.
[33]  E. H. Lee, S. K. Park, B. Park et al., “Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis,” Breast Cancer Research and Treatment, vol. 122, no. 1, pp. 11–25, 2010.
[34]  T. Byrski, J. Gronwald, T. Huzarski et al., “Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy,” Journal of Clinical Oncology, vol. 28, no. 3, pp. 375–379, 2010.
[35]  J. Boyd, Y. Sonoda, M. G. Federici et al., “Clinicopatholic features of BRCA-linked and sporadic ovarian cancer,” Journal of the American Medical Association, vol. 283, no. 17, pp. 2260–2265, 2000.
[36]  J. M. J. Piek, B. Torrenga, B. Hermsen et al., “Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study,” Familial Cancer, vol. 2, no. 2, pp. 73–78, 2003.
[37]  R. A. Lacour, S. N. Westin, L. A. Meyer et al., “Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations,” Gynecologic Oncology, vol. 121, no. 2, pp. 358–363, 2011.
[38]  A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki, “Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the National Israeli Study of Ovarian Cancer,” Journal of Clinical Oncology, vol. 26, no. 1, pp. 20–25, 2008.
[39]  J. M. Hall, M. K. Lee, B. Newman et al., “Linkage of early-onset familial breast cancer to chromosome 17q21,” Science, vol. 250, no. 4988, pp. 1684–1689, 1990.
[40]  R. Wooster, S. L. Neuhausen, J. Mangion et al., “Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13,” Science, vol. 265, no. 5181, pp. 2088–2090, 1994.
[41]  A. Meindl, “Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population,” International Journal of Cancer, vol. 97, no. 4, pp. 472–480, 2002.
[42]  J. P. Struewing, P. Hartge, S. Wacholder et al., “The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews,” New England Journal of Medicine, vol. 336, no. 20, pp. 1401–1408, 1997.
[43]  K. J. Patel, V. P. C. C. Yu, H. Lee et al., “Involvement of Brca2 in DNA repair,” Molecular Cell, vol. 1, no. 3, pp. 347–357, 1998.
[44]  M. E. Moynahan, J. W. Chiu, B. H. Koller, and M. Jasint, “Brca1 controls homology-directed DNA repair,” Molecular Cell, vol. 4, no. 4, pp. 511–518, 1999.
[45]  M. E. Moynahan, A. J. Pierce, and M. Jasin, “BRCA2 is required for homology-directed repair of chromosomal breaks,” Molecular Cell, vol. 7, no. 2, pp. 263–272, 2001.
[46]  R. Scully, J. Chen, A. Plug et al., “Association of BRCA1 with Rad51 in mitotic and meiotic cells,” Cell, vol. 88, no. 2, pp. 265–275, 1997.
[47]  S. K. Sharan, M. Morimatsu, U. Albrecht et al., “Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2,” Nature, vol. 386, no. 6627, pp. 804–810, 1997.
[48]  F. Xia, D. G. Taghian, J. S. DeFrank et al., “Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8644–8649, 2001.
[49]  J. L. Berliner and A. M. Fay, “Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors,” Journal of Genetic Counseling, vol. 16, no. 3, pp. 241–260, 2007.
[50]  D. G. R. Evans, F. Lalloo, A. Cramer et al., “Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing,” Journal of Medical Genetics, vol. 46, no. 12, pp. 811–817, 2009.
[51]  J. E. Stopfer, “Genetic counseling and clinical cancer genetics services,” Seminars in Surgical Oncology, vol. 18, no. 4, pp. 347–357, 2000.
[52]  M. B. Daly, J. E. Axilbund, S. Buys et al., “Genetic/familial high-risk assessment: breast and ovarian—clinical practice guidelines in oncology?,” Journal of the National Comprehensive Cancer Network, vol. 8, no. 5, pp. 562–594, 2010.
[53]  U.S. Preventive Services Task Force, “Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement,” Annals of Internal Medicine, vol. 143, pp. 355–361, 2005.
[54]  American Congress of Obstetricians and Gynecologists Bulletins, “Hereditary breast and ovarian cancer syndrome,” Gynecologic Oncology, vol. 113, pp. 6–11, 2009.
[55]  National Institute for Health and Clinical Excellence, “Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care,” 2006.
[56]  J. Balma?a, O. Díez, and M. Castiglione, “BRCA in breast cancer: ESMO clinical recommendations,” Annals of Oncology, vol. 20, supplement 4, pp. 19–20, 2009.
[57]  M. L. Holland, A. Huston, and K. Noyes, “Cost-effectiveness of testing for breast cancer susceptibility genes,” Value in Health, vol. 12, no. 2, pp. 207–216, 2009.
[58]  W. A. Berg, J. D. Blume, J. B. Cormack et al., “Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer,” Journal of the American Medical Association, vol. 299, no. 18, pp. 2151–2163, 2008.
[59]  A. I. Hagen, K. A. Kvistad, L. Maehle et al., “Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series,” Breast, vol. 16, no. 4, pp. 367–374, 2007.
[60]  A. J. Rijnsburger, I.-M. Obdeijn, R. Kaas et al., “BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC screening study,” Journal of Clinical Oncology, vol. 28, no. 36, pp. 5265–5273, 2010.
[61]  G. Trecate, D. Vergnaghi, S. Manoukian et al., “MRI in the early detection of breast cancer in women with high genetic risk,” Tumori, vol. 92, no. 6, pp. 517–523, 2006.
[62]  S. J. Lord, W. Lei, P. Craft et al., “A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer,” European Journal of Cancer, vol. 43, no. 13, pp. 1905–1917, 2007.
[63]  D. G. Evans, K. N. Gaarenstroom, D. Stirling et al., “Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers,” Journal of Medical Genetics, vol. 46, no. 9, pp. 593–597, 2009.
[64]  H. F. A. Vasen, E. Tesfay, H. Boonstra et al., “Early detection of breast and ovarian cancer in families with BRCA mutations,” European Journal of Cancer, vol. 41, no. 4, pp. 549–554, 2005.
[65]  E. R. Woodward, H. V. Sleightholme, A. M. Considine, S. Williamson, J. M. McHugo, and D. G. Cruger, “Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective,” International Journal of Obstetrics and Gynaecology, vol. 114, no. 12, pp. 1500–1509, 2007.
[66]  N. M. van der Velde, M. J. E. Mourits, H. J. G. Arts, et al., “Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?” International Journal of Cancer, vol. 124, pp. 919–923, 2009.
[67]  B. A. Goff, L. S. Mandel, C. W. Drescher et al., “Development of an ovarian cancer symptom index: possibilities for earlier detection,” Cancer, vol. 109, no. 2, pp. 221–227, 2007.
[68]  L. C. Hartmann, T. A. Sellers, D. J. Schaid et al., “Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers,” Journal of the National Cancer Institute, vol. 93, no. 21, pp. 1633–1637, 2001.
[69]  T. R. Rebbeck, T. Friebel, H. T. Lynch et al., “Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group,” Journal of Clinical Oncology, vol. 22, no. 6, pp. 1055–1062, 2004.
[70]  A. Finch, M. Beiner, J. Lubinski, et al., “Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation,” Journal of the American Medical Association, vol. 296, no. 2, pp. 185–192, 2006.
[71]  T. R. Rebbeck, N. D. Kauff, and S. M. Domchek, “Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers,” Journal of the National Cancer Institute, vol. 101, no. 2, pp. 80–87, 2009.
[72]  S. M. Domchek, T. M. Friebel, C. F. Singer et al., “Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality,” Journal of the American Medical Association, vol. 304, no. 9, pp. 967–975, 2010.
[73]  J. C. Boughey, T. L. Hoskin, A. C. Degnim et al., “Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer,” Annals of Surgical Oncology, vol. 17, no. 10, pp. 2702–2709, 2010.
[74]  M. S. Beattie, B. Crawford, F. Lin, E. Vittinghoff, and J. Ziegler, “Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers,” Genetic Testing and Molecular Biomarkers, vol. 13, no. 1, pp. 51–56, 2009.
[75]  T. M. Friebel, S. M. Domchek, S. L. Neuhausen et al., “Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers,” Clinical Breast Cancer, vol. 7, no. 11, pp. 875–882, 2007.
[76]  A. W. Kurian, B. M. Sigal, and S. K. Plevritis, “Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers,” Journal of Clinical Oncology, vol. 28, no. 2, pp. 222–231, 2010.
[77]  R. Kroiss, V. Winkler, K. Kalteis et al., “Prevalence of pre-malignant and malignant lesions in prophylactic mastectomy specimens of BRCA1 mutation carriers: comparison with a control group,” Journal of Cancer Research and Clinical Oncology, vol. 134, no. 10, pp. 1113–1121, 2008.
[78]  A. Finch, P. Shaw, B. Rosen, J. Murphy, S. A. Narod, and T. J. Colgan, “Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers,” Gynecologic Oncology, vol. 100, no. 1, pp. 58–64, 2006.
[79]  J. E. Hirst, G. B. Gard, K. Mcillroy, D. Nevell, and M. Field, “High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy,” International Journal of Gynecological Cancer, vol. 19, no. 5, pp. 826–829, 2009.
[80]  S. Salvador, B. Gilks, M. K?bel, D. Huntsman, B. Rosen, and D. Miller, “The fallopian tube: primary site of most pelvic high-grade serous carcinomas,” International Journal of Gynecological Cancer, vol. 19, no. 1, pp. 58–64, 2009.
[81]  M. H. Greene, P. L. Mai, and P. E. Schwartz, “Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?” American Journal of Obstetrics and Gynecology, vol. 204, no. 1, pp. 19.e1–19.e6, 2011.
[82]  B. Fisher, J. P. Costantino, D. L. Wickerham et al., “Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study,” Journal of the National Cancer Institute, vol. 90, no. 18, pp. 1371–1388, 1998.
[83]  M. C. King, S. Wieand, K. Hale et al., “Tamoxifen and breast cancer incidence among women with inherited mutations in brca1 and brca2 national surgical adjuvant breast and bowel project (nsabp-p1) breast cancer prevention trial,” Journal of the American Medical Association, vol. 286, no. 18, pp. 2251–2256, 2001.
[84]  J. Gronwald, N. Tung, W. D. Foulkes et al., “Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update,” International Journal of Cancer, vol. 118, no. 9, pp. 2281–2284, 2006.
[85]  S. W. Duffy and R. M. Nixon, “Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations,” British Journal of Cancer, vol. 86, no. 2, pp. 218–221, 2002.
[86]  K. Metcalfe, H. T. Lynch, P. Ghadirian et al., “Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2328–2335, 2004.
[87]  S. A. Narod, J. S. Brunet, P. Ghadirian, et al., “Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group,” The Lancet, vol. 356, pp. 1876–1881, 2000.
[88]  K. A. Metcalfe, D. Birenbaum-Carmeli, J. Lubinski et al., “International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers,” International Journal of Cancer, vol. 122, no. 9, pp. 2017–2022, 2008.
[89]  M. E. Beiner, A. Finch, B. Rosen et al., “The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study,” Gynecologic Oncology, vol. 104, no. 1, pp. 7–10, 2007.
[90]  D. Vicus, B. Rosen, J. Lubinski et al., “Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers,” Gynecologic Oncology, vol. 115, no. 1, pp. 135–137, 2009.
[91]  V. G. Vogel, J. P. Costantino, D. L. Wickerham et al., “Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial,” Journal of the American Medical Association, vol. 295, no. 23, pp. 2727–2741, 2006.
[92]  V. G. Vogel, J. P. Costantino, D. L. Wickerham et al., “Erratum: effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial,” Journal of the American Medical Association, vol. 298, no. 9, p. 973, 2007.
[93]  S. Iodice, M. Barile, N. Rotmensz et al., “Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis,” European Journal of Cancer, vol. 46, no. 12, pp. 2275–2284, 2010.
[94]  S. A. Narod, M. P. Dubé, J. Klijn et al., “Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers,” Journal of the National Cancer Institute, vol. 94, no. 23, pp. 1773–1779, 2002.
[95]  J. C. Figueiredo, R. W. Haile, L. Bernstein et al., “Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study,” Breast Cancer Research and Treatment, vol. 120, no. 1, pp. 175–183, 2010.
[96]  T. R. Rebbeck, T. Friebel, T. Wagner et al., “Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7804–7810, 2005.
[97]  A. Eisen, J. Lubinski, J. Gronwald et al., “Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers,” Journal of the National Cancer Institute, vol. 100, no. 19, pp. 1361–1367, 2008.
[98]  S. Abbas, L. Beckmann, J. Changclaude et al., “Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women,” Breast Cancer Research and Treatment, vol. 120, no. 3, pp. 727–736, 2010.
[99]  N. Turner, A. Tutt, and A. Ashworth, “Hallmarks of ‘BRCAness’ in sporadic cancers,” Nature Reviews Cancer, vol. 4, no. 10, pp. 814–819, 2004.
[100]  C. Bozzetti, B. Bortesi, and C. Merisio, “Loss of heterozygosity (LOH) in ovarian cancer,” International Journal of Gynecology and Obstetrics, vol. 85, no. 3, pp. 294–295, 2004.
[101]  V. Birgisdottir, O. A. Stefansson, S. K. Bodvarsdottir, H. Hilmarsdottir, J. G. Jonasson, and J. E. Eyfjord, “Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer,” Breast Cancer Research, vol. 8, no. 4, article R38, 2006.
[102]  J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden, “Sporadic epithelial ovarian cancer: clinical relevance of brca1 inhibition in the DNA damage and repair pathway,” Journal of Clinical Oncology, vol. 26, no. 19, pp. 3259–3267, 2008.
[103]  M. Thrall, H. H. Gallion, R. Kryscio, M. Kapali, D. K. Armstrong, and J. A. Deloia, “BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study,” International Journal of Gynecological Cancer, vol. 16, no. 1, pp. 166–171, 2006.
[104]  J. Weberpals, K. Garbuio, A. O'Brien, et al., “The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer,” International Journal of Cancer, vol. 124, pp. 806–815, 2009.
[105]  H. Lambie, A. Miremadi, S. E. Pinder et al., “Prognostic significance of BRCA1 expression in sporadic breast carcinomas,” Journal of Pathology, vol. 200, no. 2, pp. 207–213, 2003.
[106]  Q. Yang, T. Sakurai, I. Mori et al., “Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas,” Cancer, vol. 92, no. 1, pp. 54–60, 2001.
[107]  M. Taron, R. Rosell, E. Felip et al., “BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer,” Human Molecular Genetics, vol. 13, no. 20, pp. 2443–2449, 2004.
[108]  M. Margeli, B. Cirauqui, E. Castella et al., “The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer,” PLoS ONE, vol. 5, no. 3, 2010.
[109]  J. E. Quinn, C. R. James, G. E. Stewart et al., “BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy,” Clinical Cancer Research, vol. 13, no. 24, pp. 7413–7420, 2007.
[110]  J. I. Weberpals, D. Tu, J. A. Squire, et al., “Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study 5,” Annals of Oncology. In press.
[111]  T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R. A. Sharma, “DNA repair pathways as targets for cancer therapy,” Nature Reviews Cancer, vol. 8, no. 3, pp. 193–204, 2008.
[112]  P. C. Fong, D. S. Boss, T. A. Yap et al., “Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers,” New England Journal of Medicine, vol. 361, no. 2, pp. 123–134, 2009.
[113]  A. Tutt, M. Robson, J. E. Garber et al., “Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial,” The Lancet, vol. 376, no. 9737, pp. 235–244, 2010.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133